ES2107806T3 - Nuevos esteroides. - Google Patents

Nuevos esteroides.

Info

Publication number
ES2107806T3
ES2107806T3 ES94903944T ES94903944T ES2107806T3 ES 2107806 T3 ES2107806 T3 ES 2107806T3 ES 94903944 T ES94903944 T ES 94903944T ES 94903944 T ES94903944 T ES 94903944T ES 2107806 T3 ES2107806 T3 ES 2107806T3
Authority
ES
Spain
Prior art keywords
hydrogen
halo
dotted line
alcoxide
link
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903944T
Other languages
English (en)
Inventor
Michael John Ashton
Sven Jan-Anders Karlsson
Bernard Yvon Jack Vacher
Michael Thomas Withnall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer Ltd
Original Assignee
Rhone Poulenc Rorer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929226917A external-priority patent/GB9226917D0/en
Priority claimed from GB939303121A external-priority patent/GB9303121D0/en
Application filed by Rhone Poulenc Rorer Ltd filed Critical Rhone Poulenc Rorer Ltd
Application granted granted Critical
Publication of ES2107806T3 publication Critical patent/ES2107806T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN ESTEROIDES DE LA FORMULA (I) EN DONDE LA LINEA PUNTEADA ES INDEPENDIENTEMENTE EN CADA UNA DE LAS POSICIONES 1,2, 4,5- Y 6,7-, UN ENLACE SIMPLE O DOBLE; R1 ES UN ALQUIL C1-C4 O UN ALQUENIL C2-C4 DE CADENA RECTA O RAMIFICADA; R2 ES HIDROGENO O METIL; R3 ES ALQUIL C1-C7, FENIL, FENIL SUSTITUIDO, HETEROARIL, HETEROARIL SUSTITUIDO O -CH2R EN DONDE R ES HALO, HIDROXIDO, ALCOXIDO C1-C5 O ALCANOILOXIDO C1-C10; R4 ES HIDROGENO, HALO, HIDROXIDO, QUETO O ALCOXIDO C1-C3 CUANDO LA LINEA PUNTEADA EN LA POSICION 6, 7 FORMA UN ENLACE SIMPLE, O HIDROGENO, HALO O ALCOXIDO C1-C3 CUANDO LA LINEA PUNTEADA EN LA POSICION 6,7 FORMA UN ENLACE DOBLE; R5 ES HIDROGENO O HALO; R6 ES HIDROGENO CUANDO LA LINEA PUNTEADA EN LA POSICION 1,2 FORMA UN ENLACE SIMPLE O HIDROGENO O CLORO CUANDO LA LINEA PUNTEADA EN LA POSICION 1,2 FORMA UN ENLACE DOBLE; Y N ES 0-2; ASIMISMO SE PRESENTAN MEZCLAS RACEMICAS Y DIASTEREOISOMEROS DE LOS MISMOS, PROCESOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA SU USO, ESPECIALMENTE COMO ANTIINFLAMATORIOS.
ES94903944T 1992-12-24 1993-12-24 Nuevos esteroides. Expired - Lifetime ES2107806T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929226917A GB9226917D0 (en) 1992-12-24 1992-12-24 Novel compositions of matter
GB939303121A GB9303121D0 (en) 1993-02-17 1993-02-17 Novel compositions of matter

Publications (1)

Publication Number Publication Date
ES2107806T3 true ES2107806T3 (es) 1997-12-01

Family

ID=26302221

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903944T Expired - Lifetime ES2107806T3 (es) 1992-12-24 1993-12-24 Nuevos esteroides.

Country Status (19)

Country Link
US (1) US5801165A (es)
EP (1) EP0675897B1 (es)
JP (1) JP2657982B2 (es)
KR (1) KR960700265A (es)
AT (1) ATE154607T1 (es)
AU (1) AU672669B2 (es)
CA (1) CA2149777C (es)
CZ (1) CZ159195A3 (es)
DE (1) DE69311742T2 (es)
DK (1) DK0675897T3 (es)
ES (1) ES2107806T3 (es)
FI (1) FI953130A0 (es)
GR (1) GR3024641T3 (es)
HU (1) HUT72442A (es)
IL (1) IL108167A0 (es)
NO (1) NO952532L (es)
NZ (1) NZ259401A (es)
PL (1) PL309402A1 (es)
WO (1) WO1994014834A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9507135D0 (en) * 1995-04-06 1995-05-31 Rh Ne Poulenc Rorer Limited Chemical compounds
WO1997024368A1 (en) * 1995-12-29 1997-07-10 Glaxo Group Limited 17beta-(2-oxo-tetrahydrofuran-4-yl)-thio-androstane derivatives (17beta-(gamma-butyric acid lactone)-thio derivatives) for the treatment of inflammation and pharmaceutical compositions and a process for the production thereof
CN1245982C (zh) 1996-05-09 2006-03-22 阿姆瑞德手术有限公司 哮喘和气道疾病的治疗
HRP20010018A2 (en) 2001-01-09 2002-12-31 Pliva D D Novel anti-inflammatory compounds
RS20050008A (sr) 2002-07-08 2007-06-04 Pliva-Istraživački Institut D.O.O., Nova jedinjenja,kompozicije i metode za lečenje inflamatornih oboljenja i stanja
AU2003264917A1 (en) 2002-07-08 2004-01-23 Pliva - Istrazivacki Institut D.O.O. Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
HRP20030324A2 (en) 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
HRP20030604A2 (en) 2003-07-25 2005-04-30 Pliva-Istra�iva�ki institut d.o.o. Substituted furochromenes, preparation thereof andtheir antiinflammatory action
HRP20030603A2 (en) 2003-07-25 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. Substituted furochromene compounds of antiinflammatory action
ES2337915T3 (es) 2004-10-27 2010-04-30 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Conjugados con adtividad antiinflamatoria.
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
PT105138B (pt) * 2010-06-01 2012-11-06 Hovione Farmaciencia S A Método para a preparação de compostos orgânicos monofluorometilados biologicamente activos
PT105723B (pt) * 2011-05-26 2014-03-24 Hovione Farmaci Ncia S A Método para a preparação de compostos orgânicos biologicamente activos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3198792A (en) * 1962-06-12 1965-08-03 Philips Corp 10alpha methyl, 9beta hormonal steroids
SE378109B (es) * 1972-05-19 1975-08-18 Bofors Ab
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
GB2137206B (en) * 1980-02-15 1985-04-03 Glaxo Group Ltd Androstane 17-carbothioc acid derivatives
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
US4361559A (en) * 1981-08-20 1982-11-30 E. R. Squibb & Sons, Inc. Antiinflammatory 17,17-bis (substituted thio) androstenes
HU182775B (en) * 1981-10-15 1984-03-28 Richter Gedeon Vegyeszet Process for preparing new 3-chloro-pregnane derivatives
US4481144A (en) * 1984-02-03 1984-11-06 E. R. Squibb & Sons, Inc. 17-Substituted thia-17-alkyl(or alkenyl or alkynyl)androstenes
US4499021A (en) * 1984-04-12 1985-02-12 E. R. Squibb & Sons, Inc. 17β(Substituted thio)-16-ketoandrostene-17α..-carboxylic acid derivatives
US4528138A (en) * 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4529547A (en) * 1984-06-20 1985-07-16 E.R. Squibb & Sons, Inc. 17-(substituted thio)-17-(substituted dithio)androstenes
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
US4868170A (en) * 1987-11-13 1989-09-19 E. R. Squibb & Sons, Inc. Steriod lotion formulation
US4868169A (en) * 1987-11-13 1989-09-19 E. R. Squibb & Sons, Inc. Steroid cream formulation
US4883792A (en) * 1989-01-17 1989-11-28 Peter Timmins Steroid cream formulation

Also Published As

Publication number Publication date
NZ259401A (en) 1996-10-28
DE69311742D1 (de) 1997-07-24
EP0675897A1 (en) 1995-10-11
IL108167A0 (en) 1994-04-12
EP0675897B1 (en) 1997-06-18
JPH08504806A (ja) 1996-05-28
GR3024641T3 (en) 1997-12-31
DE69311742T2 (de) 1998-01-08
CZ159195A3 (en) 1996-03-13
PL309402A1 (en) 1995-10-02
ATE154607T1 (de) 1997-07-15
US5801165A (en) 1998-09-01
AU672669B2 (en) 1996-10-10
FI953130L (fi) 1995-06-22
DK0675897T3 (da) 1998-01-26
HUT72442A (en) 1996-04-29
CA2149777A1 (en) 1994-07-07
JP2657982B2 (ja) 1997-09-30
WO1994014834A1 (en) 1994-07-07
NO952532D0 (no) 1995-06-23
FI953130A7 (fi) 1995-06-22
NO952532L (no) 1995-08-24
HU9501876D0 (en) 1995-08-28
FI953130A0 (fi) 1995-06-22
CA2149777C (en) 2004-05-25
AU5819694A (en) 1994-07-19
KR960700265A (ko) 1996-01-19

Similar Documents

Publication Publication Date Title
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2107806T3 (es) Nuevos esteroides.
ES2114931T3 (es) Nuevos esteres esteroidales.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2012809B3 (es) Derivados del taxol, su preparacion y composiciones farmaceuticas que los contienen.
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
ES2101063T3 (es) Derivados monofluorados de n-propargil-1-amino-indano y su utilizacion como inhibidores de la monoamin-oxidasa.
ES2146741T3 (es) Derivados de rapamicina utiles como inmunosupresores.
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
MX9100990A (es) Compuesto monohidrato de furoato de mometasona,al procedimiento para su preparacion y a las composiciones farmaceuticas
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
AR021355A1 (es) Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
DK0775155T3 (da) Estra-1,3,5,(10)-trien derivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
UY26920A1 (es) 7 - oxo piridopirimidinas
ES8606879A1 (es) Un procedimiento para la preparacion de derivados esteroida-les
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
ES2121597T3 (es) Derivados de bencenosulfonamida para el tratamiento de la inestabilidad de la vejiga.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 675897

Country of ref document: ES